Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 4/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2048941 | 0.94 | CASP2 (0.70) | CASP2NAAAFAAHCNR1DNM1 | |
| SCHEMBL937406 | 0.92 | CASP2 (0.74) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL28420676 | 0.92 | CASP2 (0.74) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL5537985 | 0.92 | CASP2 (0.74) | CASP2NAAAFAAHDNM1EPHX1 | |
| SCHEMBL5545255 | 0.89 | CASP2 (0.59) | CASP2NAAAFAAHCNR1DNM1 | |
| SCHEMBL5536463 | 0.88 | FAAH (0.59) | CASP2NAAAFAAHCNR1DNM1 | |
| SCHEMBL2050472 | 0.86 | — | — | |
| SCHEMBL2318684 | 0.86 | CASP2 (0.71) | CASP2NAAAFAAHCNR1DNM1 | |
| SCHEMBL7552938 | 0.86 | FAAH (0.62) | CASP2NAAAFAAHCNR1DNM1 | |
| SCHEMBL5544292 | 0.86 | FAAH (0.62) | CASP2NAAAFAAHCNR1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0034326-B1 | CHIRAL POLYSILOXANES, PROCESS FOR THEIR PREPARATION AND THEIR USE | Bayer, Ernst, Prof. Dr. (DE) | 1984-07-25 | — | — | EP | claimed |
| US-4387206-A | CHROMATOGRAPHY | BAYER ERNST (DE) | 1983-06-07 | — | — | US | claimed |
| CN-112110891-A | Tellurolactone and method for preparing ditellurium compound by using same | 清华大学 | 2020-12-22 | — | — | CN | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8598162-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2287162-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-2287161-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-2284169-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| EP-1471901-A1 | SPERMIDINE DERIVATIVES FOR THE TREATMENT OF CHRONIC NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTHAMPTON (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-6797699-B1 | EXEMPLIFIED BY N'-L-ARGINYLSPERMIDINE | UNIVERSITY OF SOUTHAMPTON (GB) | 2004-09-28 | — | — | US | disclosed |
| US-20040106560-A1 | Neuroprotective agents | SUNDSTROM LARS ERIC (GB) | 2004-06-03 | — | — | US | disclosed |
| WO-2003066037-A1 | SPERMIDINE DERIVATIVES FOR THE TREATMENT OF CHRONIC NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTHAMPTON (GB) | 2003-08-14 | — | — | WO | disclosed |
| EP-1040096-B1 | NEUROPROTECTIVE AGENTS | UNIV SOUTHAMPTON (GB) | 2003-07-09 | — | — | EP | disclosed |
| US-6150351-A | ADMINISTERING AN EFFECTIVE AMOUNT OF THE CEPHEM COMPOUND TO A PATIENT SUFFERING FROM DISEASES CAUSED BY HELICOBACTER PYLORI | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-21 | — | — | US | disclosed |
| EP-1040096-A1 | NEUROPROTECTIVE AGENTS | THE UNIVERSITY OF SOUTHAMPTON (GB) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999031049-A1 | NEUROPROTECTIVE AGENTS | UNIVERSITY OF SOUTHAMPTON (GB) | 1999-06-24 | — | — | WO | disclosed |
| EP-0034326-B1 | CHIRAL POLYSILOXANES, PROCESS FOR THEIR PREPARATION AND THEIR USE | Bayer, Ernst, Prof. Dr. (DE) | 1984-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | CASP2 2874/4885NAAA 1503/4885FAAH 249/4885 |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | CASP2 2874/4885NAAA 1503/4885FAAH 249/4885 |
| US-20040106560-A1 | Neuroprotective agents | NLN, DDO, TXN | CASP2 82/4885NAAA 2074/4885FAAH 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.